PER 6.90% 8.1¢ percheron therapeutics limited

Ann: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK, page-11

  1. 13,064 Posts.
    lightbulb Created with Sketch. 1353
    “In parallel with commencement of the trial, the Company is pleased to be enhancing its patient advocacy interactions with Dr Gil Price’s participation in the upcoming Parent Project Muscular Dystrophy (PPMD) 9th annual conference (29 June to 1 July 2023; https://web.cvent.com/event/f695ea28-c338-4307-bbd3-c5b27a9fae3e/summary) where he will present on ATL1102 and the Phase IIb study.”

    Someone was asking for Gil Price to attend the PPMD conference..this am
    Wow! Management must be reading HC.

    Now : GP has something to deliver $$. . Hope PPMD will give Anp the attention they have given Sarepta.

    Up Up and away !!


    Last edited by itsagas: 27/06/23
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.1¢
Change
-0.006(6.90%)
Mkt cap ! $73.02M
Open High Low Value Volume
8.7¢ 8.7¢ 8.1¢ $154.2K 1.820M

Buyers (Bids)

No. Vol. Price($)
2 33824 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.4¢ 275242 2
View Market Depth
Last trade - 16.10pm 24/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.